Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer

Clinical studies suggest that responses to HPV16 E6E7L2 fusion protein (TA-CIN) vaccination alone are modest, and GPI-0100 is a well-tolerated, potent adjuvant. Here we sought to optimize both the immunogenicity of TA-CIN via formulation with GPI-0100 and treatment of HPV16+ cancer by vaccination af...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Shiwen, Wang, Joshua W., Karanam, Balasubramanyam, Wang, Chenguang, Huh, Warner K., Alvarez, Ronald D., Pai, Sara I., Hung, Chien-fu, Wu, T. -C., Roden, Richard B. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283968/
https://www.ncbi.nlm.nih.gov/pubmed/25560237
http://dx.doi.org/10.1371/journal.pone.0116389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283968/
https://www.ncbi.nlm.nih.gov/pubmed/25560237
http://dx.doi.org/10.1371/journal.pone.0116389

Ejemplares similares